Liver cancer remains one of the most lethal malignancies worldwide and it has been found that the canonical Wnt signalling governed by its effector β-catenin playing an important role in development of this malignancy. In the liver, it has been unravelled as both an oncogenic pathway involved in a subset of liver cancers and a physiological signalling identified as the “zonation-keeper” of the quiescent liver lobule. β-catenin regulates both its upstream and downstream effector proteins viz. TCF-4 and COX-2 respectively. β-catenin binds to both the COX-2 RNA stabilising proteins CUGBP2 and HuR protein, where the latter two has antagonistic function. This duality has encouraged exploring the role of canonical Wnt in liver regeneration and liver-cell proliferation. We will review here the current knowledge concerning β-catenin and its downstream signalling as biomarker in liver cancer.